Vivian Shi, MD
Dermatology · Seattle, WANPI 1720333990
Payments from drug & device makers
Across 848 payments — averaging $1333.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$311K
- Sanofi$158K
- Novartis$119K
- Incyte Corporation$99K
- Regeneron Healthcare Solutions, Inc.$93K
- UCB, Inc.$92K
- plus $259K from 20 others
Across 23 payments — averaging $1793.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$18K
- Pfizer$15K
- AbbVie$4K
- UCB, Inc.$2K
- Sanofi$1K
What the payments were for
- Consulting fees$575,54859%
- Speaking & faculty fees$324,87633%
- Grants$5,2771%
- Travel & lodging$50,5825%
- Food & beverage$14,4771%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 184 | $310,788 |
| Sanofi | 98 | $157,820 |
| Novartis | 109 | $118,737 |
| Incyte Corporation | 64 | $98,626 |
| Regeneron Healthcare Solutions, Inc. | 110 | $93,409 |
| UCB, Inc. | 104 | $92,396 |
| LEO Pharma AS | 18 | $70,349 |
| Eli Lilly | 21 | $41,243 |
| Dermavant Sciences, Inc. | 19 | $31,597 |
| Regeneron | 4 | $26,423 |
| LEO Pharma Inc. | 12 | $23,036 |
| Lilly USA, LLC | 53 | $21,719 |
| Pfizer | 7 | $17,468 |
| Dermira, Inc. | 15 | $16,160 |
| Genentech, Inc. | 1 | $3,330 |
| UCB SA | 3 | $2,573 |
| Boehringer Ingelheim | 2 | $1,944 |
| Sun Pharmaceutical Industries Inc. | 1 | $800 |
| Almirall LLC | 1 | $800 |
| Bsn Medical Inc | 1 | $600 |
| Galderma Laboratories, L.p. | 5 | $435 |
| Sanofi-aventis U.S. LLC | 6 | $185 |
| E.r. Squibb & Sons, L.L.C. | 3 | $92 |
| Johnson & Johnson | 3 | $48 |
| Musculoskeletal Transplant Foundation Inc. | 3 | $45 |
| Arcutis Biotherapeutics, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,130,646 in reported general payments places this provider in the 95th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 61 | $717,626 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $146,748 |
| Dupixent PenDupilumab | 21 | $74,978 |
| Triamcinolone Acetonide | 29 | $351 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Seattle
- Michi ShinoharaSeattle$277K
- James CollyerSeattle$115K
- Alison YoungSeattle$53K
- Sonja KrejciSeattle$53K
- Paul NghiemSeattle$35K
- Andrew LinSeattle$19K
- John ScopettaSeattle$15K
- Tien NguyenSeattle$13K
- Paula ZookSeattle$12K
- Cory SimpsonSeattle$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.